There is a general consensus that residual DNA from immortalised cells is very unlikely to pose a safety risk for biotechnology products but there is little experimental data to support this contention. Transgenic mice primed with one or more oncogenes or tumour suppressor deletions offer a potentially sensitive and quantitative method for determining the presence of oncogenic DNA. Separate lines of mice transgenic for myc and Cbfa1 may provide a means of detecting oncogenic DNA containing genes belonging to different complementation groups.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.
Blood
December 2024
St. Jude Children's Research Hospital, Memphis, Tennessee, United States.
Inotuzumab Ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide inter-patient variability in treatment response, and the genetic basis of this variation remains largely unknown. Using a genome-wide CRISPR screen, we discovered the loss of DNTT as a primary driver of InO resistance.
View Article and Find Full Text PDFLeveraging prior knowledge for process parameter classification in mAb Protein A chromatography.
J Chromatogr A
December 2024
Eli Lilly and Company, Indianapolis, IN 46285, USA.
Protein A (ProA) affinity chromatography plays an essential role in purifying monoclonal antibodies (mAbs) and their analogues by reducing impurities like residual host cell proteins (HCPs), residual DNA, process additives, and potential viral contaminants. Decades of mAb process development and commercialization efforts have built extensive prior knowledge in the Protein A process. The prior knowledge facilities streamlined process development and minimized the need for extensive process characterization studies to inform manufacturing control strategies.
View Article and Find Full Text PDFUltrasensitive Detection and Monitoring of Circulating Tumor DNA using Structural Variants in Early-Stage Breast Cancer.
Clin Cancer Res
January 2025
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Purpose: The detection of circulating tumor DNA (ctDNA) after curative-intent therapy in early breast cancer (EBC) is highly prognostic of disease recurrence. Current ctDNA assays, mainly targeting single nucleotide variants (SNVs), vary in sensitivity and specificity. While increasing the number of SNVs in tumor-informed assays improves sensitivity, structural variants (SVs) may achieve similar or better sensitivity without compromising specificity.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Penn Alzheimer's Disease Research Center, University of Pennsylvania, Philadelphia, PA, USA.
Background: Atypical presentations of Alzheimer's disease (AD), which demonstrate more cortical involvement relative to medial temporal lobe (MTL), are generally associated with younger age of onset. Age, defined chronologically, is a primary driver of AD pathology and neurodegeneration. However, some young onset cases are typical, amnestic presentations and some older onset cases present more cortical atrophy.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Neurology, University of Cologne, Medical Faculty, Cologne, Germany.
Background: Age represents the predominant risk factor for Alzheimer's disease (AD) dementia. Nevertheless, not every elderly individual undergoes age-related processes that inevitably lead to dementia. The aging process is characterized by cellular senescence, manifesting as morphological changes and the secretion of immune signaling mediators linked to systemic low-grade inflammation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!